News

Eli Lilly and Company: Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with ...

PEDS, Mounjaro met the primary and all key secondary endpoints at 30 weeks and showed sustained improvement in glycemic control and continued BMI reduction ...
TAG24 on MSN

How to get more fibre into your diet – and why it matters for seniors

Fibre might not steal the spotlight on your plate, but it plays a vital role in keeping us healthy – especially as we age.Despite its many health benefits, from supporting digestion to reducing the ...